Dr Reddys Laboratories Limited and AstraZeneca Pharma India Limited (AZPIL) signed a distribution agreement for Riax, a new brand of saxagliptin and Riax-M a fixed dose combination of saxagliptin with metformin. Both Riax and Riax M are trademarks of the AstraZeneca group. AZPIL already has two brands under the trademark Onglyza and Kombiglyze for saxagliptin and in fixed-dose combination with metformin respectively, promoted and distributed in the Indian market.
Onglyza (saxagliptin), AstraZenecas patented therapy, is an oral hypoglycemic (anti-diabetic therapy) in the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings.
Alok Sonig, Senior Vice President and Head of India Business, Dr .Reddys Laboratories Limited said, We are committed to addressing unmet needs of diabetes patients in India and are pleased to partner with AstraZeneca in launching saxagliptin and its combination with metformin, an important addition to our Diabetes franchise. This will expand access to innovative medicines to vast number of diabetes patients in India.
Sanjay Murdeshwar, Managing Director, AstraZeneca Pharma India Limited commenting on the partnership said, Diabetes is a disease of epidemic scale in India with over 65 million affected people. We at AstraZeneca are committed to transforming patient care in Diabetes by offering innovative treatment options across the spectrum. This partnership reflects our constant endeavor to enhance patients access to novel treatment solutions like saxagliptin
Dr. Reddys Laboratories Ltd will be distributing Riax and Riax M in India.